Insilico Medicine is pending an IPO on the Hong Kong Stock Exchange, aiming to raise approximately $293 million to fund its AI-driven drug discovery.
Insilico Medicine is pending an IPO on the Hong Kong Stock Exchange, aiming to raise approximately $293 million to fund its AI-driven drug discovery.
| Underwriter |
|---|
Morgan StanleyLEAD |
CICC |
Insilico Medicine went public on December 30, 2025.
Insilico Medicine is listed on the Hong Kong Stock Exchange.
The Insilico Medicine IPO was underwritten by Morgan Stanley, CICC.